Here at IMS, we are dedicated to the advancement of medicine through our work in Research & Development.
Since 2007, IMS has been involved in clinical trials to further the medical community’s knowledge of various diseases and medications for treatment.
In addition to traditional therapies used in gastroenterology, we are proud to be able to offer our patients access to novel therapies otherwise unavailable to the general public through the clinical trial programs we offer.
As a Center for Therapeutic Innovation, we partner with the world’s leading physicians and pharmaceutical developers in order to provide our patients with the most cutting edge information on the most innovative therapies.
Our team has been involved in the development of several FDA approved medications, a few of them being Xeljanz®, Harvoni®, Sovaldi®, Entyvio®, Xifaxan®, Veikira Pak®, Asacol HD® and Uceris®.
Below are some of the studies which are currently open for enrollment.
Call or complete the form to the right to discuss your eligibility in one of our programs that are now being offered.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn’s Disease Who Have Inadequately Responded to or Are Intolerant to Anti-TNF Therapy.
One Year Study of Rifaximin Delayed Release (DR) Tablets in Crohn’s Disease.
A Study of the Safety and Efficacy of Etrolizumab in Patients With Moderately to Severely Active Crohn’s Disease Inhibitors.
Safety and Efficacy of GS-5745 in Participants With Moderately to Severely Active Crohn’s Disease.
A Study of the Efficacy and Safety of Etrolizumab in Ulcerative Colitis Patients Who Are Refractory to or Intolerant of TNF Inhibitors.
Safety and Efficacy of APD334 in Patients With Ulcerative Colitis.
Safety and Efficacy of GS-5745 in Adults With Moderately to Severely Active Ulcerative Colitis Disease.
A Randomized, Double-Blind, Double-Dummy, Multicenter, Active-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab IV Compared to Adalimumab SC in Subjects With Ulcerative Colitis.
Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C)
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection.